Cargando…

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)

SIMPLE SUMMARY: High grade serous ovarian cancer (HGSOC) is the most common and lethal subtype of ovarian cancer without effective therapeutic options. The high prevalence of mutations (~96%) in tumor suppressor p53 is a hallmark of HGSOC. Estrogen receptor-beta (ERβ) has been reported to be another...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oturkar, Chetan C., Gandhi, Nishant, Rao, Pramod, Eng, Kevin H., Miller, Austin, Singh, Prashant K., Zsiros, Emese, Odunsi, Kunle O., Das, Gokul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909529/ https://www.ncbi.nlm.nih.gov/pubmed/35267428 http://dx.doi.org/10.3390/cancers14051120

Ejemplares similares

Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
por: Gandhi, Nishant, et al.
Publicado: (2021)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis
por: Pavlič, Renata, et al.
Publicado: (2022)

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer
por: Starbuck, Kristen D., et al.
Publicado: (2018)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
por: Barger, Carter J, et al.
Publicado: (2021)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
por: Fotopoulou, Christina, et al.
Publicado: (2021)

Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis
por: Iżycka, Natalia, et al.
Publicado: (2023)

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
por: Barger, Carter J., et al.
Publicado: (2015)

Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling
por: Pham, Thu Ha, et al.
Publicado: (2021)

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies
por: Cavarzerani, Enrico, et al.
Publicado: (2023)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine
por: Wu, Nayiyuan, et al.
Publicado: (2023)

Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes
por: Cunnea, Paula, et al.
Publicado: (2023)

FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer
por: Yang, Yuhan, et al.
Publicado: (2020)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC
por: Xu, Jing, et al.
Publicado: (2023)

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells
por: Chesnokov, Mikhail S., et al.
Publicado: (2021)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression
por: Agnani, Deep, et al.
Publicado: (2011)

Analysis of survivin, XIAP and FoxM1 as potential chemoresistance factors in breast cancer cells
por: Moraes, Gabriela N, et al.
Publicado: (2013)

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells
por: Chiu, Wen-Tai, et al.
Publicado: (2014)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
por: Sheta, Razan, et al.
Publicado: (2020)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC
por: Xi, Yue, et al.
Publicado: (2023)

Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation
por: Mistarz, Anna, et al.
Publicado: (2021)

The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC
por: Li, Jiajia, et al.
Publicado: (2022)

MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC
por: Zhuang, Xucui, et al.
Publicado: (2023)

Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
por: Gandhi, Nishant, et al.
Publicado: (2019)

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study
por: Eng, Kevin H., et al.
Publicado: (2018)

Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery
por: Mark, Jaron, et al.
Publicado: (2018)

Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes
por: Zhu, Qianqian, et al.
Publicado: (2019)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
por: Matthews, Bayley G., et al.
Publicado: (2021)

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma
por: Nunes, Mariana, et al.
Publicado: (2022)

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
por: Mukhopadhyay, Utpal K, et al.
Publicado: (2019)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hjqfm0ptfarp60cle8js0juebv